Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin/MPA (PREMPRO) and MPA Suspension (Provera) in Healthy Postmenopausal Women

Trial Profile

Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin/MPA (PREMPRO) and MPA Suspension (Provera) in Healthy Postmenopausal Women

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2010

At a glance

  • Drugs Conjugated estrogens/medroxyprogesterone; Medroxyprogesterone
  • Indications Menopausal syndrome
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 21 Jun 2010 Company added as trial sponsor as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Actual end date added to 1 Apr 2008 as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top